Medtronic shares reached a session high on Friday amid hopes of expanded reimbursement for renal denervation, a hypertension therapy used in the company’s Symplicity Spyral Renal Denervation System. The uptick came after the AMA CPT Editorial Panel released a Proposed Panel Agenda for its upcoming meeting, including a proposal to establish permanent Category I codes for RDN therapy. Leerink Partners analyst Mike Kratky called this a meaningful potential step towards expanded reimbursement that could incrementally drive adoption for Medtronic's RDN business. Subject to a positive review at the September 2026 meeting, the proposed migration from Category III to Category I indicates that available clinical data and utilization trends are supportive of granting a permanent code for RDN. While a favorable Panel action would not by itself guarantee coverage or a payment rate, it de-risks the reimbursement pathway that has been a key overhang on RDN adoption since the technology's launch.
Medtronic PLCProposed permanent Category I codes for RDN therapy would de-risk reimbursement pathway, a key overhang on adoption.